OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Altern ...

Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ:NVDA). The sector is also getting a lift from the U.S. Federal Reserve’s decision to stop raising rates and its suggestions that it will cut rates later this year. Lower rates make it much easier for drug makers to obtain funds to finance the development of pharmaceuticals. Meanwhile, many pharmaceutical firms have rather low valuations because they dropped sharply in ...

Nasdaq-listed Exscientia shares crashed by more than a fifth as the Oxford-based biotech fired its founder and chief executive over "inappropriate relationships" with two employees. In a statement, the AI-focused drug developer said that Andrew Hopkins's behaviour was inconsistent with “the company’s standards and values”. Hopkins has been removed from his role on the board effective immediately, with a special committee established and an outside counsel appointed to look into his behaviour. Chairman David ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using the company’s deep learning, single-cell precision medicine platform and actual patient clinical response. The EXCYTE-2 study will collect blood and bone marrow samples from first-line patients with AML, with an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 6-K ___________________________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 OR 15d-16 of the Securities Exchange Act of 1934 for the Month of May 2023 Commission File Number: 001-40850 ___________________________________ Exscientia plc (Translation of registrant's name into English) ___________________________________ The Schrödinger Building Oxford Science Park Oxford OX4 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 13(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Exscientia Business and Financial Update for the Full Year 2022 OXFORD, U.K. - Exscientia plc (Nasdaq: EXAI) Recent developments in the Company's pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below. Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a.m. EDT. "2022 was marked by significant milestones for Exscientia, including signing a groundbreaking strategic collaboration with Sanofi, as we cont ...

Timeline for illustrative purposes EXS74539 ('539) (LSD1 inhibitor) • LSD1 demethylates histones, playing a critical role in suppressing the expression of genes required for cellular differentiation • Drives the proliferation and survival of several tumour types • LSD1 is overexpressed in many cancer types across haematology and oncology • Inhibiting LSD1 reactivates expression of genes driving differentiation; can inhibit cell growth and sensitise any remaining cells to other agents A brain penetrant LSD1 ...

Financial Data and Key Metrics Changes - The company reported cash inflows from collaborations of $117 million for the first nine months of 2022, compared to $67.5 million in the same period of 2021, indicating significant growth in collaboration revenue [61] - Net operating cash outflows were $15 million for the first nine months of 2022, a decrease from net operating cash inflows of $8.3 million in the same period of 2021, reflecting increased investments in growth initiatives [62] - The company ended the quarter with approximately $625 million in cash equivalents and bank deposits, providing several years of cash runway [63] Business Line Data and Key Metrics Changes - The company is advancing its clinical pipeline with plans to initiate a Phase 1b/2 study for EXS-21546 by the end of 2022 and expects to file a clinical trial application for GTAEXS-617 by the end of 2022 [8][11] - The collaboration with Sanofi is expanding to include an additional oncology target, showcasing the company's ability to leverage partnerships for growth [12] Market Data and Key Metrics Changes - The company is expanding its focus into biologics design, which effectively doubles the addressable target universe of its precision medicine platform [54] - The collaboration with the University of Texas, MD Anderson Cancer Center aims to develop small molecule therapies in oncology, indicating a strategic move into high-potential markets [12] Company Strategy and Development Direction - The company aims to shift the economic curve of the pharmaceutical industry by improving the probability of success, accelerating development cycles, and reducing costs through innovative clinical strategies [14] - The integration of AI in drug discovery and development is a core part of the company's strategy, with a focus on patient-centered precision medicine [52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to advance multiple programs, including EXS-21546 and GTAEXS-617, while also investing in long-term growth initiatives [63] - The management highlighted the increasing interest in AI from pharmaceutical companies, indicating a favorable environment for collaborations and partnerships [84] Other Important Information - The company is utilizing a generative design approach for biologics, which is expected to enhance the speed and quality of drug development [71] - The company has made significant progress in developing a precision medicine platform that integrates AI and deep learning to improve patient selection for clinical trials [52] Q&A Session Summary Question: Can you discuss the ramp-up of the biologics focus and how it will evolve? - Management indicated that moving into biologics effectively doubles the target universe and expects to show proof-of-concept experiments in 2023 [67] Question: What improvements can the platform provide for biologics drug development? - Management confirmed that the generative design approach will lead to cost and time reductions in getting drugs to the IND phase [70] Question: How does the ABS patient signature work in the clinic? - The company aims to match the right treatment to the right patients using biomarker signatures, with ongoing studies to build confidence in these signatures [76] Question: Can you elaborate on the collaboration with MD Anderson? - The collaboration focuses on leveraging Exscientia's small molecule design capabilities alongside MD Anderson's clinical research expertise [96] Question: What is the sentiment around AI from pharma companies? - Management noted an increased interest in AI within big pharma, with ongoing discussions for collaborations [84]

✈ Exscientia 3Q 2022 Business Update November 15, 2022 Forward-looking statements This presentation and accompanying oral presentation (referred to herein collectively as the "presentation") contain express and implied forwardlooking statements that involve substantial risks and uncertainties. All statements contained in this presentation, other than statements of historical facts, including statements regarding expectations of Exscientia plc ("we," "us", "our," or "Exscientia"), our strategy, future operat ...